RU2012113380A - OPHTHALMIC COMPOSITIONS CONTAINING DORZOLAMIDE, THYMOL AND BRIMONIDINE - Google Patents
OPHTHALMIC COMPOSITIONS CONTAINING DORZOLAMIDE, THYMOL AND BRIMONIDINE Download PDFInfo
- Publication number
- RU2012113380A RU2012113380A RU2012113380/15A RU2012113380A RU2012113380A RU 2012113380 A RU2012113380 A RU 2012113380A RU 2012113380/15 A RU2012113380/15 A RU 2012113380/15A RU 2012113380 A RU2012113380 A RU 2012113380A RU 2012113380 A RU2012113380 A RU 2012113380A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- hydroxyethyl cellulose
- amount
- present
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Abstract
1. Офтальмологическая композиция, содержащаяa) дорзоламид;b) тимолол;c) бримонидин;d) ги дроксиэтилцеллюлозу;и одно или более фармацевтически приемлемых вспомогательных веществ.2. Композиция по п.1, где дорзоламид присутствует в количестве 2% в/о композиции.3. Композиция по п.1, где тимолол присутствует в количестве 0,5% в/о композиции.4. Композиция по п.1, где бримонидин присутствует в количестве 0,2% в/о композиции.5. Композиция по п.1, где гидроксиэтилцеллюлоза используется в качестве усилителя стабильности.6. Композиция по п.1, где гидроксиэтилцеллюлоза используется в качестве усилителя растворимости.7. Композиция по п.1, где вязкость композиции составляет от приблизительно 20 сП до приблизительно 120 сП.8. Композиция по п.1, где композиция имеет рН от приблизительно 5 до приблизительно 7.9. Композиция по п.1, где композиция упакована в контейнер из ПЭНП.10. Композиция по п.1, где композиция стабильна в течение более шести месяцев.11. Композиция по п.1, где размер капли композиции составляет от приблизительно 35 мкл до приблизительно 45 мкл.12. Композиция по п.11, где размер капли композиции составляет 40 мкл.13. Композиция по п.1, где гидроксиэтилцеллюлоза имеет вязкость от приблизительно 40 сП до приблизительно 200 сП.14. Композиция по п.1, где гидроксиэтилцеллюлоза присутствует в количестве от приблизительно 0,1% в/о до приблизительно 1% в/о композиции.15. Композиция по п.14, где гидроксиэтилцеллюлоза присутствует в количестве от приблизительно 0,2% в/о до приблизительно 0,8% в/о композиции.16. Композиция по п.14, где гидроксиэтилцеллюлоза присутствует в количестве от приблизительно 0,3% в/о до приблизительно 0,6% в/о композиции.17. Способ лечения глазной гипе�1. An ophthalmic composition comprising a) dorzolamide; b) timolol; c) brimonidine; d) hydroxyethyl cellulose; and one or more pharmaceutically acceptable excipients. 2. The composition of claim 1, wherein dorzolamide is present in an amount of 2% w / v of the composition. The composition of claim 1, wherein timolol is present in an amount of 0.5% w / v of the composition. The composition of claim 1, wherein brimonidine is present in an amount of 0.2% w / v of the composition. The composition of claim 1, wherein the hydroxyethyl cellulose is used as a stability enhancer. The composition of claim 1, wherein the hydroxyethyl cellulose is used as a solubility enhancer. The composition of claim 1, wherein the viscosity of the composition is from about 20 cP to about 120 cP. The composition of claim 1, wherein the composition has a pH of from about 5 to about 7.9. The composition of claim 1, wherein the composition is packaged in a LDPE container. The composition of claim 1, wherein the composition is stable for more than six months. The composition of claim 1, wherein the droplet size of the composition is from about 35 μl to about 45 μl. The composition of claim 11, wherein the droplet size of the composition is 40 μl. The composition of claim 1, wherein the hydroxyethyl cellulose has a viscosity of from about 40 cP to about 200 cP. The composition of claim 1, wherein the hydroxyethyl cellulose is present in an amount of from about 0.1% w / v to about 1% w / v of the composition. The composition of claim 14, wherein the hydroxyethyl cellulose is present in an amount of from about 0.2% w / v to about 0.8% w / v of the composition. The composition of claim 14, wherein the hydroxyethyl cellulose is present in an amount of from about 0.3% w / v to about 0.6% w / v of the composition. A method for treating ocular hype
Claims (22)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2151CH2009 | 2009-09-07 | ||
IN2151/CHE/2009 | 2009-09-07 | ||
PCT/IN2010/000591 WO2011027365A2 (en) | 2009-09-07 | 2010-09-03 | Ophthalmic compositions containing dorzolamide, timolol and brimonidine |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012113380A true RU2012113380A (en) | 2013-10-20 |
Family
ID=43429374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012113380/15A RU2012113380A (en) | 2009-09-07 | 2010-09-03 | OPHTHALMIC COMPOSITIONS CONTAINING DORZOLAMIDE, THYMOL AND BRIMONIDINE |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2012113380A (en) |
WO (1) | WO2011027365A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA117768C2 (en) * | 2013-12-24 | 2018-09-25 | Сентісс Фарма Прайвет Лімітед | Topical brimonidine tartrate ophthalmic solution |
TWI751136B (en) * | 2016-02-22 | 2022-01-01 | 日商參天製藥股份有限公司 | Medical composition containing dorzolamide and brimonidine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008027340A2 (en) * | 2006-08-30 | 2008-03-06 | Merck & Co., Inc. | Topical ophthalmic formulations |
MX2007010025A (en) | 2007-08-17 | 2009-02-25 | Arturo Jimenez Bayardo | Pharmaceutical composition for treatment of ocular hypertension. |
MX2007011165A (en) | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Pharmaceutically stable compound consisting of timolol, dorzolamide and brimonidine. |
-
2010
- 2010-09-03 RU RU2012113380/15A patent/RU2012113380A/en unknown
- 2010-09-03 WO PCT/IN2010/000591 patent/WO2011027365A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2011027365A3 (en) | 2011-06-23 |
WO2011027365A2 (en) | 2011-03-10 |
WO2011027365A9 (en) | 2011-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015205268B2 (en) | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition | |
RU2013124024A (en) | PHARMACEUTICAL COMPOSITION CONTAINING MOMETASONE FUROAT AND AZELASTINE HYDROCHLORIDE, NASAL INTRODUCTION | |
US7105512B2 (en) | Ophthalmic aqueous pharmaceutical preparation | |
JP5650947B2 (en) | Ophthalmic composition for ionic silicone hydrogel contact lens | |
AR082049A1 (en) | LIQUID FORMULATIONS OF RUPATADINA FUMARATO | |
EA005676B1 (en) | Salt of perindopril and pharmaceutical compositions containing it | |
PE20070120A1 (en) | DERIVATIVES OF PROSTAGLANDIN | |
RU2013107744A (en) | BIMATOPROST AND THYMOLOL SOLUTIONS NOT CONTAINING CONSERVANTS | |
JP2017186372A5 (en) | ||
JP2023062143A (en) | aqueous composition | |
RU2012113380A (en) | OPHTHALMIC COMPOSITIONS CONTAINING DORZOLAMIDE, THYMOL AND BRIMONIDINE | |
JP2019178083A (en) | Aqueous solution for eye drops | |
CN1438886A (en) | Ophthalmic solution | |
JP5922609B2 (en) | Aqueous composition containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid | |
RU2012124216A (en) | PHARMACEUTICAL COMBINATION OF PROSTAGLANDINE AND NSAID COMPOUNDS FOR TREATMENT OF GLAUCOMA AND EYE HYPERTENSION | |
JP6132968B1 (en) | Pharmaceutical composition containing dorzolamide, polymer and boric acid | |
JP2011105706A (en) | Ophthalmic agent | |
JP2009040727A (en) | Stable eye lotion containing latanoprost as active ingredient | |
JP2014009162A (en) | Aqueous composition for ophthalmology | |
JP6628924B2 (en) | Aqueous liquid | |
JP4832015B2 (en) | Oxyglutathione-containing aqueous solution | |
JP2005247777A (en) | Ophthalmic agent | |
RU2011151807A (en) | LIQUID OPHTHALMIC PHARMACEUTICAL COMPOSITIONS CONTAINING PROPIONIC ACID DERIVATIVES AS A CONSERVANT | |
TW201517904A (en) | Ophthalmic composition for zwitterionic soft contact lens | |
JP2024052135A (en) | Water-based liquid |